home / stock / zntl / zntl news

ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 12/02/21

Stock Information
Company Name: Zentalis Pharmaceuticals Inc.
Stock Symbol: ZNTL
Market: NASDAQ
Website: zentalis.com
Menu
ZNTL ZNTL Quote ZNTL Short ZNTL News ZNTL Articles ZNTL Message Board
Get ZNTL Alerts

News, Short Squeeze, Breakout and More Instantly...
ZNTL - Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021

NEW YORK and SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is hosting a virtual R&...
ZNTL - FDA grants Fast Track tag for Zentalis Pharma's ZN-c3 in uterine serous carcinoma

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announces that the FDA has granted Fast Track designation to ZN-c3, an oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma (USC) in adult women. Fast Track status provides for more frequent interac...

ZNTL - Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

NEW YORK and SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that th...

ZNTL - Zentalis Pharmaceuticals EPS beats by $1.22

Zentalis Pharmaceuticals (NASDAQ:ZNTL): Q3 GAAP EPS of -$0.09 beats by $1.22. Cash, cash equivalents and marketable securities of of $366.8M Press Release For further details see: Zentalis Pharmaceuticals EPS beats by $1.22

ZNTL - Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

Initiated a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma Enrollment ongoing in the potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC) Published seminal resear...

ZNTL - Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that An...

ZNTL - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2021 Update

Halvorsen's 13F portfolio value decreased marginally from $33.58B to $32.98B this quarter. The number of positions decreased from 94 to 88. Viking Global added FIGS Inc. & JD.com and increased Amazon.com & General Electric during the quarter. The top three positions are Am...
ZNTL - Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma

NEW YORK and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that t...

ZNTL - Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021

NEW YORK and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that s...

ZNTL - Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3

NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pu...
Previous 10 Next 10